Mar 15, 2023 / 01:30PM GMT
Brian R. Mueller - BioMarin Pharmaceutical Inc. - Executive VP of Finance & CFO
As Gena mentioned, I'll start with just a few slides to orient you with the company, and then we'll -- I'll be brief so we can get into the Q&A. Briefly, forward-looking statements. I'll be making comments on BioMarin's future business prospects. So I definitely encourage you to review all of our disclosures in our SEC filings, including risk factors in our most recently filed Form 10-K.
I'll also comment on some non-GAAP financial measures. These are not meant to be reviewed in isolation or as a substitute for GAAP and are provided as supplemental information to highlight some of our operating performance.
So BioMarin is a best-in-class genetic disease company at an inflection point of transformative growth. Captured here are the 3 cornerstones to our investment thesis that I'll review with you briefly. It all starts with this solid, profitable IRA insulated and growing base business of mostly enzyme-based therapies that generate nearly $2 billion of revenue as well as positive operating cash flows.
Biomarin Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers